海南医学院学报2023，Vol.29Issue(24)：1904-1913,10.DOI:10.13210/j.cnki.jhmu.20221128.002
结核分枝杆菌药物作用机理及耐药机制研究进展
Research progress on the drug action and resistance mechanism in Mycobacterium tuberculosis
摘要
Abstract
Tuberculosis(TB)is a chronic infectious disease caused by Mycobacterium tuberculosis(MTB).It is the sec-ond largest single cause of death besides novel coronavirus pneumonia.Along with the abuse of antibiotics and extensive use of anti-tuberculosis drugs,multidrug-resistant(MDR)TB,extensive drug-resistant(XDR)TB and totally drug-resistant(TDR)TB became obstacles to the tuberculosis eradication worldwide.According to the World Health Organization statistics,China is not on-ly a high burden tuberculosis country in the world,but also a country with a serious epidemic of MDR.Traditional drugs fail to meet the needs of tuberculosis control.Therefore,it is urgent to find new targets of anti-tuberculosis drugs and develop new anti-tuberculosis drugs.Hence,this paper systematically summarizes the mechanism of traditional and newly developed anti-tuberculo-sis drugs,in which the research progress of drug resistance mechanisms are mainly focused.This work provides us with new in-sights of new anti-tuberculosis drug developments,and may contribute to a reduction in the harm that tuberculosis brings to society.关键词
抗结核药物/结核分枝杆菌/耐药机制/多耐药结核Key words
Anti-tuberculosis drugs/Mycobacterium tuberculosis/Resistance mechanism/Multidrug resistance tuberculosis分类
医药卫生引用本文复制引用
葛赛,宋欣怡,姜惠跃,李昭阳,朱壮彦,孙曼銮..结核分枝杆菌药物作用机理及耐药机制研究进展[J].海南医学院学报,2023,29(24):1904-1913,10.基金项目
This study was supported by Fundamental Research Program of Shanxi province(202103021223339 （）
20210302124435) （）
Shanxi Scholarship Council of China(2022-175) （2022-175）
Fundamental Research Program of Shanxi Datong University(2019Q2 （）
2019Q4) （）
Doctoral Scientific Research Foundation of Shanxi Datong University(2018-B-13 （）
2018-B-28) 山西省基础研究计划(202103021223339 （）
20210302124435),山西省回国留学人员科研资助项目(2022-175) （2022-175）
山西大同大学青年科研基金(2019Q2 （）
2019Q4) （）
山西大同大学博士科研启动金(2018-B-13 （）
2018-B-28) （）
